Altimmune to Participate in the 9th Annual Evercore Healthcare Conference
Altimmune, Inc. announced its management will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference on Tuesday, December 1, 2026, at 3:25 p.m. ET. A webcast of the event will be available on the company's website. Altimmune is a biopharmaceutical company developing pemvidutide, a dual glucagon/GLP-1 receptor agonist, for serious liver diseases like MASH and alcohol-associated liver disease.
At $1.4187 a share, Altimmune (ALT) accounting officer Richard Menziuso bought 10,000 shares.
Altimmune, Inc. (ALT) Principal Accounting Officer Richard Thomas Menziuso purchased 10,000 shares of common stock at $1.4187 per share on November 18, 2026. This open market transaction increased his direct holdings to 10,000 shares. The Form 4 filing also noted that three other insiders had made open-market purchases of Altimmune stock in the 30 days prior to this filing.
Altimmune (ALT) executive Menziuso bought 10,000 shares for $14.2K at $1.42
Richard Thomas Menziuso, Principal Accounting Officer at Altimmune Inc. (ALT), purchased 10,000 shares of the company's common stock for $14,187 at a price of $1.42 per share on November 18, 2026. This open-market purchase increased his direct holdings to 10,000 shares. The transaction was reported via an SEC Form 4 filing.
A 9.99% ownership cap limits TCG funds’ warrant exercises at Altimmune (ALT).
TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P. reported warrants for 10 million Altimmune (ALT) common shares. These warrants include a beneficial ownership limitation, restricting exercise if it would result in the holder and affiliates owning more than 9.99% of Altimmune's outstanding shares. Chen Yu, the sole managing member of both general partners, is deemed to share voting and dispositive power over these 10 million shares, representing 4.9% of the class.
Altimmune Inc Lobbying Profile, 2020
This page provides a lobbying profile for Altimmune Inc. It indicates that as of July 23, 2026, Altimmune Inc. had $0 in total federal lobbying spending for 2022, with no direct spending or spending through subsidiaries. The data is based on calculations by OpenSecrets using information from the Senate Office of Public Records, covering January 1 to June 30 for the most recent year.
Altimmune (ALT) CFO surrenders 5,672 shares solely to cover stock vesting taxes.
Altimmune, Inc. (ALT) CFO Gregory L. Weaver converted 18,750 restricted stock units into common shares on November 11, 2026. He subsequently surrendered 5,672 shares, valued at $1.93 per share, exclusively to cover taxes related to the RSU vesting. Following these transactions, Weaver's reported RSU balance was 37,500 units.
Form 4 Altimmune Inc: Jerome Benedict Durso (Director, President and CEO) For: 13 November
This article reports on a Form 4 filing for Altimmune Inc, detailing an insider transaction by Jerome Benedict Durso, who holds positions as Director, President, and CEO. The filing is specific to November 13. The brief announcement provides no further details about the nature of the transaction.
A purchase at $1.635 a share brings Altimmune (ALT) director Pisano’s direct holdings to 58,800.
Altimmune, Inc. Director Wayne Pisano purchased 10,000 shares of common stock at $1.635 per share on November 13, 2026, increasing his direct holdings to 58,800 shares. This transaction was reported via an SEC Form 4 filing, with no Rule 10b5-1 plan indicated.
CEO buys shares at $1.6187 each in Altimmune (ALT), bringing his direct holdings to 93,200.
Altimmune, Inc. (ALT) President and CEO Jerome Benedict Durso purchased 30,700 shares of common stock on November 13, 2026, at a price of $1.6187 per share. This transaction increased his directly held position to 93,200 shares. The purchase was not made under a Rule 10b5-1 plan, and two other insiders also reported open-market purchases of ALT stock in the 30 days prior to this filing.
Insider Buyers Lose Additional US$201k As Altimmune Dips To US$375m
Insiders who bought Altimmune, Inc. (NASDAQ:ALT) stock for US$370.0k at an average price of US$3.52 over the last year have seen their investment decrease by 18% to US$169.4k. Despite this loss, the article highlights that Chairman Jerome Durso previously bought shares at a higher price of US$3.54, indicating prior confidence in the company. While insider ownership is low at 0.5%, there have been no insider sales in the past year, only purchases.
ALT Q3 Earnings Miss, Stock Sinks on Higher Costs & Funding Concerns
Altimmune (ALT) reported a wider-than-expected loss of 15 cents per share in Q3 2026, with no revenues generated. The company's R&D and general and administrative expenses significantly increased, leading to investor concerns. Shares of ALT dropped nearly 17% following the announcement, reflecting worries over rising clinical development costs and funding uncertainty for its phase III AUD program.
What Altimmune (ALT) Said on Its Q3 Earnings Call
Altimmune (ALT) provided updates on its Q3 earnings call, highlighting the ramp-up of its Phase III PERFORMA trial for MASH and preparations for a December FDA meeting regarding a Phase III program for alcohol use disorder (AUD). The company reported a wider net loss due to increased R&D spending but confirmed sufficient cash reserves to fund operations through the PERFORMA readout. Additionally, Altimmune plans to seek non-dilutive funding for the AUD program.
Altimmune Q3 2026 Earnings Call Transcript
Altimmune reported a net loss of $31.6 million for Q3 2026, driven by increased R&D expenses for its MASH Phase 3 and ALD Phase 2 trials. The company holds $480 million in cash and is pursuing non-dilutive funding. Altimmune is advancing pemvidutide for various liver diseases, with strong progress in its PERFORMA Phase 3 trial for MASH and positive Phase 2 results for AUD, leading to an upcoming FDA meeting.
Altimmune, Inc. (ALT) Misses Q3 EPS by 2c
Altimmune, Inc. (NASDAQ: ALT) reported its Q3 EPS, missing analyst estimates by $0.02 with a reported ($0.15) against an estimated ($0.13). The company's stock price was $1.76, down 8.81% on the day of the report. Investors can access historical earnings data for Altimmune, Inc. on StreetInsider.com.
Altimmune Misses As Phase 3 Spending Ramps; Pipeline Advances, But Shares Sit Near A 52-Week Low
Altimmune reported a wider-than-expected third-quarter loss of $0.15 per share, attributed to increased spending as its lead asset, pemvidutide, entered a global Phase 3 trial for MASH. While clinical progress was made across multiple fronts, including the PERFORMA trial and a concrete plan for its AUD program, the rising costs and unsecured funding for the AUD Phase 3 trial are causing investor concern, leading to the stock trading near a 52-week low. The company faces scrutiny regarding enrollment numbers for PERFORMA and funding for the AUD program.
ALT: Altimmune Inc. filed SEC Form 8-K: Results of Operations and...
Altimmune Inc. (ALT) filed an SEC Form 8-K, reporting a Q3 2026 net loss of $31.6 million, or $0.15 per share, an increase from $19.0 million a year prior, largely due to rising R&D expenses. Despite the loss, the company holds $480 million in cash and has key FDA meetings scheduled for its MASH and alcohol use disorder (AUD) programs, with positive designations received for both. However, the increase in outstanding shares has led to dilution for existing shareholders.
Altimmune Reports Positive Phase 2 RECLAIM Results for Pemvidutide in Alcohol Use Disorder and Announces FDA Meeting Plans for Phase 3 Program
Altimmune, Inc. announced positive results from its RECLAIM Phase 2 study for pemvidutide in treating moderate-to-severe alcohol use disorder (AUD), showing significant reductions in heavy drinking days and improved clinical outcomes. The investigational drug, a balanced 1:1 glucagon/GLP-1 dual receptor agonist, was generally well tolerated, with primarily mild-to-moderate gastrointestinal side effects. Altimmune plans to meet with the FDA in December to discuss the design of a Phase 3 registrational program for AUD.
Altimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026
Altimmune (ALT) announced that data from its RECLAIM Phase 2 trial of pemvidutide for alcohol use disorder (AUD) has been accepted for a late-breaking oral presentation at The Liver Meeting® 2026. The trial met its primary endpoint, showing a statistically significant reduction in heavy drinking days, and also achieved key secondary endpoints validated by the FDA as registrational endpoints. Altimmune is scheduled to meet with the FDA in December to discuss the Phase 3 registrational program for pemvidutide in AUD.
Altimmune to present alcohol use disorder trial data Monday By Investing.com
Altimmune Inc. (NASDAQ:ALT) announced that data from its RECLAIM Phase 2 trial for pemvidutide in adults with moderate-to-severe alcohol use disorder will be presented at The Liver Meeting on Monday, November 9, 2026. The trial showed a statistically significant reduction in heavy drinking days and other key secondary endpoints. The company plans to meet with the FDA in December 2026 to discuss the Phase 3 registrational program.
Altimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
Altimmune, Inc. (Nasdaq: ALT) announced it will report its third quarter 2026 financial results on Thursday, November 12, 2026. The company will host a conference call at 8:30 a.m. ET on the same day to discuss the results and provide a business update, which will be webcast live on its Investor Relations website. Altimmune is a biopharmaceutical company focused on developing pemvidutide for serious liver diseases, including metabolic dysfunction-associated steatohepatitis (MASH) and alcohol-associated liver disease (ALD).
Director receives 160,000 stock options at Altimmune (ALT), exercisable at $2.02 a share.
Altimmune, Inc. (ALT) director Peter Greenleaf was granted 160,000 stock options on November 2, 2026, with an exercise price of $2.02 per share. These options will vest monthly over 36 months, contingent on his continued service. The options are set to expire on November 2, 2036.
Altimmune, Inc. (ALT) Seasonal Returns Chart
This article provides a seasonal returns chart for Altimmune, Inc. (ALT), displaying the average monthly price return from 2017 to 2026. The stock was trading at $2.0200 at close on November 2, with a slight pre-market change.
Altimmune, Inc. (ALT) Seasonal returns chart
This article provides a seasonal returns chart for Altimmune, Inc. (ALT), showing the average monthly price return from 2017 to 2026. It includes current stock price data for ALT, along with after-hours trading information. The page is part of Yahoo Finance and offers various financial data points for the company.
Altimmune adds Peter Greenleaf and Alex Howarth to board; three directors to retire
Altimmune (ALT) has announced the appointment of Peter Greenleaf and Alex Howarth to its board of directors, effective November 2, 2026. Simultaneously, current directors John Gill, Mitchell Sayare, and Klaus Schafer will retire after the 2027 annual meeting. This move brings in seasoned pharmaceutical executives and includes compensation packages for the new appointees.
Form 8K Altimmune Inc For: 27 October By Investing.com
This article reports on the filing of a Form 8K by Altimmune Inc. on October 27, 2026. The Form 8K is a crucial SEC filing used by public companies to announce major events that shareholders should know about. No specific details about the content of the Form 8K are provided in this brief announcement.
Three directors will retire in 2027 as Altimmune (ALT) names two incoming board members.
Altimmune, Inc. (Nasdaq: ALT) announced the appointment of Peter Greenleaf and Alex Howarth to its board of directors, effective November 2, 2026, increasing the board's size from nine to eleven members. Concurrently, John Gill, Mitchell Sayare, and Klaus Schafer will retire and not seek re-election at the 2027 Annual Meeting. The new directors bring extensive experience in biopharmaceutical development, commercialization, and corporate strategy, aligning with Altimmune's transition to a late-stage clinical company focused on pemvidutide for serious liver diseases.
Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution
Altimmune, Inc. has appointed Peter Greenleaf and Alex Howarth, two experienced biotech executives, to its Board of Directors, effective November 2, 2026, to support its strategic evolution as it transitions to a late-stage clinical company. This move aligns with the company's focus on developing pemvidutide for liver diseases, while three current board members, John M. Gill, Mitchel Sayare, Ph.D., and Klaus O. Schafer, M.D., MPH, will retire at the 2027 Annual Meeting. The new appointments are expected to bring valuable expertise in drug development, commercialization, and corporate strategy as Altimmune progresses its Phase 3 MASH trial and other clinical programs.
Altimmune adds two directors, three to retire ahead of 2027 meeting
Altimmune, Inc. announced the appointment of Peter Greenleaf and Alex Howarth to its board of directors, effective November 2, 2026. This move is part of a planned board transition, as John M. Gill, Mitchel Sayare, Ph.D., and Klaus O. Schafer, M.D., MPH, will retire at the company's 2027 Annual Meeting. The company is also progressing with its clinical trials for pemvidutide, an investigational drug for serious liver diseases.
Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution
Altimmune, Inc. announced the appointment of Peter Greenleaf and Alex Howarth to its board of directors, effective November 2, 2026. These additions are part of a strategic evolution as the company transitions to a late-stage clinical organization, focusing on advancing pemvidutide for serious liver diseases. Concurrently, John M. Gill, Mitchel Sayare, Ph.D., and Klaus O. Schafer, M.D., MPH, will retire from the Board at the company's 2027 Annual Meeting.
Altimmune, Inc. Estimates – NASDAQ:ALT
This article provides access to financial actuals and analyst estimates for Altimmune, Inc. (NASDAQ: ALT) on TradingView. Users can explore reported financial data across income statements, balance sheets, cash flow statements, and valuation metrics, comparing actual results with various analyst estimates and visualizing trends over time. The platform also offers detailed overviews, statements, statistics, estimates, dividends, and earnings information for the company.
Altimmune, Inc. Estimates – TRADEGATE:3G0
This article provides an overview of Altimmune, Inc. (3G0 on Tradegate Exchange) financials and estimates on TradingView. It highlights where users can explore reported financial data, analyst estimates across various statements, and compare actual results with average, high, and low estimates. The platform also allows visualization of financial trends over time for both annual and quarterly data.
Altimmune, Inc. (ALT) Stock Price, News, Quote & History
Altimmune, Inc. (ALT) closed at $2.23, down 3.04%, with after-hours trading showing a further decline. The company is a late clinical-stage biopharmaceutical firm focused on developing therapies for liver diseases, with its lead product candidate, pemvidutide, in Phase 3 trials. Analyst recommendations include an average price target of $17.11, while the company reported a Q2 FY26 revenue of $0 and earnings of -$22.82 million.
Altimmune to present pemvidutide liver disease data at AASLD By Investing.com
Altimmune Inc. (NASDAQ:ALT) will present clinical and preclinical data for its drug pemvidutide at the American Association for the Study of Liver Diseases meeting in November 2026. The presentation will include 48-week results from the IMPACT Phase 2b study for MASH, showing reductions in fibrosis markers, liver fat, and alanine aminotransferase, with mild to moderate gastrointestinal adverse events. Additionally, preclinical data on pemvidutide's effect on alcohol intake will be presented.
Altimmune to present pemvidutide liver disease data at AASLD By Investing.com
Altimmune Inc. will present clinical and preclinical data for its drug pemvidutide at the American Association for the Study of Liver Diseases meeting. The presentation will include 48-week results from its IMPACT Phase 2b study, showing pemvidutide's effectiveness in reducing markers of fibrosis and liver fat in MASH patients, along with a favorable safety profile. Additionally, preclinical data on pemvidutide's potential to reduce alcohol intake will be shared.
Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026
Altimmune, Inc. announced it will present new clinical and preclinical data on pemvidutide at The Liver Meeting® 2026. The data will highlight improvements in liver fibrosis and inflammation from the IMPACT Phase 2b study in MASH, as well as new preclinical data showing a significant reduction in alcohol intake with pemvidutide, supporting its investigation for alcohol use disorder and alcohol-associated liver disease. The company will also showcase its pipeline, including the PERFORMA Phase 3 trial, at an exhibit booth.
Altimmune to present pemvidutide liver disease data at AASLD
Altimmune Inc. (NASDAQ:ALT) is set to present clinical and preclinical data for its drug pemvidutide at the American Association for the Study of Liver Diseases meeting in November 2026. The presentation will include 48-week results from the IMPACT Phase 2b study in MASH, showing reductions in fibrosis markers, liver fat, and alanine aminotransferase, with mild to moderate gastrointestinal adverse events. Additionally, preclinical data on pemvidutide's ability to reduce alcohol intake will be shared.
Altimmune Inc. Advanced Charts | ALT
This article provides advanced chart data and financial information for Altimmune Inc. (ALT). It includes key metrics such as stock price, daily range, 52-week range, volume, market value, and analyst ratings, alongside a brief company description. The data also details short interest, EPS, and notes on data sources and delays.
Form 4 Altimmune Inc For: 12 October By Investing.com
This article announces the publication of a Form 4 filing for Altimmune Inc. dated October 12. The Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the ownership of company stock by company insiders. The article provides no further details beyond stating that the filing is available.
Form 4 Altimmune Inc For: 12 October By Investing.com
This article is a brief financial update indicating the filing of Form 4 for Altimmune Inc. on October 12th. It provides no further details beyond this announcement, functioning primarily as a placeholder or headline for the regulatory filing.
Analysts Are Bullish on These Healthcare Stocks: Madrigal Pharmaceuticals (MDGL), Altimmune (ALT)
Two healthcare stocks, Madrigal Pharmaceuticals (MDGL) and Altimmune (ALT), have received bullish ratings from analysts. H.C. Wainwright reiterated a Buy rating for Madrigal Pharmaceuticals with a $620.00 price target and a strong buy consensus with an average price target of $683.62. Altimmune also received a reiterated Buy rating from H.C. Wainwright with a $20.00 price target, and a strong buy consensus with an average price target of $19.00, representing a significant upside.
CFO surrenders 4,379 shares in Altimmune (ALT) solely to cover stock-vesting taxes.
Altimmune's Chief Financial Officer, Gregory L. Weaver, reported the vesting of 14,475 restricted stock units (RSUs) and the acquisition of an equal number of common shares on October 1, 2026. To cover the associated taxes, he surrendered 4,379 shares at $2.76 per share. Following this transaction, his RSU balance was 43,425, and his common stock holdings were 49,927 shares.
Rights to 36,234 shares accompany options with a $2.76 exercise price awarded by Altimmune (ALT).
Altimmune's Principal Accounting Officer, Richard Thomas Menziuso, was awarded 84,546 stock options with a $2.76 exercise price and 36,234 restricted stock units on October 1, 2026. Both equity awards have a four-year vesting schedule, with 25% vesting on October 1, 2027, and the remainder vesting monthly for options and annually for RSUs, contingent on his continued service. This insider transaction highlights compensation practices and long-term incentives for key executives at Altimmune.
Inventory turnover of Altimmune, Inc. – HAN:3G0
This article provides financial information for Altimmune, Inc. (HAN:3G0) listed on the Hannover Stock Exchange. Specifically, it focuses on the company's inventory turnover, indicating "No trades" at the time of publication. The content also lists various features and resources available on the TradingView platform.
Altimmune Appoints Richard Menziuso as Principal Accounting Officer
Altimmune has appointed Richard Menziuso as Vice President, Global Controller and Principal Accounting Officer, effective September 29, 2026. This move brings a seasoned finance executive with 28 years of experience to a critical accounting role. The company notes that there are no special arrangements or related-party transactions tied to this appointment, and Altimmune will enter into a standard indemnification agreement with Menziuso.
Altimmune appoints Richard Menziuso as VP, Global Controller and Principal Accounting Officer
Altimmune (ALT) has appointed Richard Menziuso as Vice President, Global Controller and Principal Accounting Officer, effective September 29, 2026. Gregory Weaver will continue in his role as Chief Financial Officer. Menziuso brings 28 years of finance and accounting experience, including 12 years in public accounting and previous roles at several pharmaceutical and medical technology companies.
Tangible book value per share of Altimmune, Inc. – HAN:3G0
This article provides financial information for Altimmune, Inc. (HAN:3G0) from TradingView, specifically focusing on its tangible book value per share. It indicates the market status as closed with no trades and mentions the data sources used.
Non-operating income (total) of Altimmune, Inc. – HAN:3G0
This article provides financial data for Altimmune, Inc. (HAN:3G0) focusing specifically on its non-operating income. The data is sourced from ICE Data Services and FactSet, with SEC filings provided by Quartr. It appears to be a snapshot from a financial data platform.
Form 8K Altimmune Inc For: 29 September By Investing.com
This article reports on an SEC Form 8K filing by Altimmune Inc. for September 29. The filing pertains to financial markets and is published by Investing.com, a platform for global financial news and data. The content is brief, primarily serving as an announcement of the filing's availability.
Altimmune appoints Richard Menziuso as vice president and principal accounting officer
Altimmune, Inc. (NASDAQ:ALT) has announced the appointment of Richard Menziuso as vice president, global controller, and principal accounting officer, effective Tuesday. Menziuso brings 28 years of finance and accounting experience, having previously served at Centessa Pharmaceuticals, Thermo Fisher Scientific, and Axovant Gene Therapies. This move follows Altimmune's recent Q2 earnings report, which indicated a narrower-than-expected loss and a strong cash balance of $519 million, as the company progresses with late-stage trials for liver disease and alcohol use disorder.
Form 8K Altimmune Inc For: 29 September By Investing.com
The article reports on Altimmune Inc.'s Form 8K filing for September 29, 2026. This brief piece, published by Investing.com, indicates a routine regulatory disclosure without providing specific details of the filing's content.